Clinical Study

An Open-Label, Single-Arm Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Early Stage Relapsing Remitting Multiple Sclerosis

Posted Date: Jun 27, 2017

  • Investigator: Lawrence Goldstick
  • Co-Investigator: Samantha Maldonado
  • Specialties:
  • Type of Study: Observational/Survey

The purpose of this study is to see if ocrelizumab (study drug) will halt the worsening of the signs and symptoms of your early stage MS. Ocrelizumab is a type of drug called a monoclonal antibody. Monoclonal antibodies act like your body’s immune syst

Criteria:

You Are Invited To Take Part In A Research Study (Also Known As A Clinical Trial) Of A Drug Called Ocrelizumab. You Were Selected As A Possible Participant In This Study Because You Have Early Stage Relapsing Remitting Form Of Multiple Sclerosis (Ms).

Keywords:

Monoclonal Antibodies, F. Hoffmann-La Roche Ltd, Multiple Sclerosis, Ocrelizumab, Relapse Remitting

For More Information:

Samantha Maldonado
937-535-5012
samantha.maldonado@uchealth.com

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.